What is Gilead Sciences's other accrued liabilities?

Gilead Sciences (GILD) reported other accrued liabilities of $3.4B in Q1 2026.

How has Gilead Sciences's other accrued liabilities changed year-over-year?

Gilead Sciences's other accrued liabilities decreased by 26.3% year-over-year, from $4.62B to $3.4B.

What is the long-term trend for Gilead Sciences's other accrued liabilities?

Over 4 years (2021 to 2025), Gilead Sciences's other accrued liabilities has grown at a -10.4% compound annual growth rate (CAGR), from $6.15B to $3.95B.

Gilead Sciences GILD Other accrued liabilities

Other accrued liabilities at other companies

Bristol-Myers SquibbBMY

$12.62B-23.6%

IncyteINCY

——

Merck & Co.MRK

——

BiogenBIIB

——

ModernaMRNA

——

Eli LillyLLY

——

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$153.66B+23.8%

Enterprise value$168.2B+19.7%

P/E16.7×-4.1×

P/S5.2×+0.8×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's other accrued liabilities?: Gilead Sciences (GILD) reported other accrued liabilities of $3.4B in Q1 2026.
How has Gilead Sciences's other accrued liabilities changed year-over-year?: Gilead Sciences's other accrued liabilities decreased by 26.3% year-over-year, from $4.62B to $3.4B.
What is the long-term trend for Gilead Sciences's other accrued liabilities?: Over 4 years (2021 to 2025), Gilead Sciences's other accrued liabilities has grown at a -10.4% compound annual growth rate (CAGR), from $6.15B to $3.95B.